The Future of Decentralized Clinical Trials

Decentralized Clinical Trials (DCTs) have increased in popularity during the pandemic. DCTs tout better patient participation, lower dropout rates, and more diverse patient pools. But as the world opens up and traditional clinical trial capacity returns to pre-pandemic levels, will DCTs maintain their popularity? Join industry experts from Bristol Myers Squibb (BMS) and Thread(R) as they discuss the merits and future of DCTs.

Scott Pearson
Chief Product Officer
Hassan Kadhim
Senior Director
Bristol Myers Squibb
James Allgood
Sr. Product Marketing Manager, Life Sciences